51 results
6-K
ASND
Ascendis Pharma A/S
2 May 24
Current report (foreign)
4:29pm
to Ophthalmology and TransCon IL-2 b/g, with €1.7 million and €1.1 million, respectively.
R&D costs for the three months ended March 31, 2024 … Risk
Inflation affects us as our vendors may pass on any increased costs to us and accordingly increase our R&D costs, SG&A expenses and cost
6-K
EX-99.1
ASND
Ascendis Pharma A/S
2 May 24
Ascendis Pharma Reports First Quarter 2024 Financial Results
4:22pm
expenses (SG&A and R&D) of approximately €600 million for 2024.
Expect to be operating cash flow breakeven on a quarterly basis by the end of 2024.
Page … and development (R&D) costs for the first quarter of 2024 were €70.7 million compared to €106.1 million during the same period in 2023. The 33% decline
6-K
EX-99.2
ASND
Ascendis Pharma A/S
2 May 24
Notice to convene Annual General Meeting 2024
4:02pm
and administration activities. Research and development costs (“R&D costs”) consist primarily of product development and pre-commercial manufacturing costs … of rendering services.
Research and Development Costs
The development of R&D costs reflects the advancement of our pipeline of endocrinology and oncology
6-K
EX-99.3
ASND
Ascendis Pharma A/S
2 May 24
Notice to convene Annual General Meeting 2024
4:02pm
US DK DE US DK DE US Selling, General and 74 25 137 101 34 170 118 51 185 Administration* R&D, Commercial 205 80 118 271 81 140 302 83 140
6-K
EX-99.1
cza5dnngo4tb eq
7 Feb 24
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
4:05pm
6-K
EX-99.1
72iy2o ds
8 Jan 24
Current report (foreign)
6:08am
6-K
vm6d8e23vs6
8 Jan 24
Current report (foreign)
6:05am
6-K
8365 4xfi
7 Nov 23
Current report (foreign)
4:03pm
6-K
EX-99.1
1vq895
7 Nov 23
Ascendis Pharma Reports Third Quarter 2023 Financial Results
4:01pm
6-K
1omfawzw
5 Sep 23
Current report (foreign)
4:14pm
6-K
EX-99.1
y4jmr
5 Sep 23
Ascendis Pharma Reports Second Quarter 2023 Financial Results
4:09pm
6-K
EX-99.1
7myb2 mum
31 May 23
Current report (foreign)
12:01pm
6-K
EX-99.2
ws9uzd 09w
2 May 23
Notice to convene Annual General Meeting 2023
4:02pm
6-K
a4bzrlgcl91ifk6z
27 Apr 23
Current report (foreign)
4:02pm
6-K
EX-99.1
uqdlz
27 Apr 23
Ascendis Pharma Reports First Quarter 2023 Financial Results
4:01pm
6-K
j94w73r2
2 Nov 22
Current report (foreign)
4:31pm
6-K
EX-99.1
f1d1nf
2 Nov 22
Ascendis Pharma Reports Third Quarter 2022 Financial Results
4:05pm
6-K
0bbsd0ysk
10 Aug 22
Current report (foreign)
4:13pm
6-K
EX-99.1
ud0wu e8zycdg
10 Aug 22
Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
4:08pm